Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Atrix Laboratories, Inc. (NasdaqNM:ATRX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
July 24Conference call: Atrix Laboratories Earnings (Q3 2001)
Location
2579 Midpoint Drive
Fort Collins, CO 80525
Phone: (970) 482-5868
Fax: (970) 482-9735
Email: rjaffe@pondel.com
Employees (last reported count): 127
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 22%
·Over the last 6 months:
 · 12 insider buys; 25.0K shares (0.8% of insider shares)
·Institutional: 28% (36% of float)
(84 institutions)
·Net Inst. Buying: 916.0K shares (+17.48%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Atrix Laboratories, Inc. is a pharmaceutical company focused on advanced drug delivery. With five patented drug delivery technologies, the Company is currently developing a diverse portfolio of products, including proprietary oncology, pain management and dermatology products. The Company also partners with large pharmaceutical and biotechnology companies to apply its proprietary technologies to new chemical entities or to extend the patent life of existing products. The Company has strategic alliances with several pharmaceutical companies including recent collaborations with Sanofi-Synthelabo Inc., Pfizer Inc., Elan, and the Novartis company, Geneva Pharmaceuticals, to use its drug delivery technologies and expertise in the development of new products.
More from Market Guide: Expanded Business Description

Financial Summary
Atrix Laboratories, Inc. is a specialty pharmaceutical company with five patented technologies that provide drug delivery from minutes to months. For the six months ended 6/30/01, revenues rose 66% to $7.5 million. Net loss applicable to Common before extraordinary item and acctg. change rose 91% to $12.4 million. Revenues reflect income recognition from oncology and pain management R&D activities. Loss reflects increased R&D expenses and a $2 million debt conversion charge.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

David Bethune, 60
Chairman and CEO
$356K
Brian Richmond, 49
CFO
--  
Richard Jackson, Ph.D., 62
Sr. VP- R&D, Director
272K
Charles Cox, Ph.D., 48
Sr. VP, Corp. Devel.
171K
Richard Dunn, 60
Sr. VP, Drug Delivery Research
167K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ATRXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 3-Apr-2001
$9.625
Recent Price$26.97 
52-Week High
on 19-July-2001
$28.40 
Beta0.46 
Daily Volume (3-month avg)177.0K
Daily Volume (10-day avg)103.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+82.1%
52-Week Change
relative to S&P500
+144.3%
Share-Related Items
Market Capitalization$410.7M
Shares Outstanding15.2M
Float11.9M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.94 
Earnings (ttm)-$2.53 
Earnings (mrq)-$0.32 
Sales (ttm)$0.97 
Cash (mrq)$3.70 
Valuation Ratios
Price/Book (mrq)13.92 
Price/EarningsN/A 
Price/Sales (ttm)27.86 
Income Statements
Sales (ttm)$13.0M
EBITDA (ttm)-$14.5M
Income available to common (ttm)-$32.8M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-49.74%
Return on Equity (ttm)-183.32%
Financial Strength
Current Ratio (mrq)7.95 
Debt/Equity (mrq)0.33 
Total Cash (mrq)$56.2M
Short Interest
As of 8-Aug-2001
Shares Short526.0K
Percent of Float4.4%
Shares Short
(Prior Month)
312.0K
Short Ratio2.04 
Daily Volume258.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.